As co-founder and CEO of Astarte Medical, Tracy leverages her experience in entrepreneurship and nearly two decades as an early stage venture capital investor. Tracy previously co-founded Astarte Ventures, an early stage investment firm focused exclusively on investing in companies with technologies to support women’s and children’s health and wellbeing. This passive portfolio includes eight companies supporting this market focus. It was through the efforts associated with Astarte Ventures, Tracy and her co-founders came together to form Astarte Medical to dramatically impact health outcomes in the first 1000 days of life, from conception through age 2.
Prior to Astarte, Tracy served as general partner at Battelle Ventures and focused on investments in health & life sciences, as well as emerging energy technologies. Tracy led the firm’s investments in NuPathe (NASDAQ: PATH; acquired by Teva Pharmaceuticals for $140 million), BioNano Genomics (NASDAQ: BNGO), Micro Interventional Devices, and SmartSynch (sold to Itron for $100 million). While at Battelle Ventures, Tracy co-founded NellOne Therapeutics, a biotechnology company focused on soft tissue regeneration.
In 2014, Tracy to co-found FedIMPACT, LLC in 2014, a commercialization enterprise to identify and launch technologies from federal laboratories. Having successfully spun-out four companies in just 18 months with over $5M of funding, FedIMPACT was acquired by IP Group, plc in December 2016.
Tracy received her BS in Accounting and International Business from New York University and her MBA at Columbia Business School in Finance.
BioNano Genomics, Endovalve, Metatomix, and NellOne Therapeutics